Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)

ClinicalTrials.gov ID: NCT01857323

Public ClinicalTrials.gov record NCT01857323. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 23, 2026, 9:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Prospective, Open-Label Assessment of the Albuterol Spiromax® DPI Integrated Dose Counter

Study identification

NCT ID
NCT01857323
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Enrollment
317 participants

Conditions and interventions

Interventions

  • Albuterol Spiromax® Drug

Drug

Eligibility (public fields only)

Age range
4 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 30, 2013
Primary completion
Jul 31, 2013
Completion
Aug 31, 2013
Last update posted
Jun 7, 2015

2013

United States locations

U.S. sites
30
U.S. states
16
U.S. cities
30
Facility City State ZIP Site status
Teva Investigational Site 10620 Phoenix Arizona
Teva Investigational Site 10637 Costa Mesa California
Teva Investigational Site 10635 Huntington Beach California
Teva Investigational Site 10647 Rolling Hills Estates California
Teva Investigational Site 10643 San Diego California
Teva Investigational Site 10644 San Jose California
Teva Investigational Site 10622 Centennial Colorado
Teva Investigational Site 10634 Denver Colorado
Teva Investigational Site 10645 Wheat Ridge Colorado
Teva Investigational Site 10633 Miami Florida
Teva Investigational Site 10640 Ormond Beach Florida
Teva Investigational Site 10641 Overland Park Kansas
Teva Investigational Site 10636 Bethesda Maryland
Teva Investigational Site 10631 North Dartmouth Massachusetts
Teva Investigational Site 10646 Plymouth Minnesota
Teva Investigational Site 10627 St Louis Missouri
Teva Investigational Site 10642 Bozeman Montana
Teva Investigational Site 10613 High Point North Carolina
Teva Investigational Site 10616 Raleigh North Carolina
Teva Investigational Site 10618 Canton Ohio
Teva Investigational Site 10615 Oklahoma City Oklahoma
Teva Investigational Site 10624 Tulsa Oklahoma
Teva Investigational Site 10625 Eugene Oregon
Teva Investigational Site 10626 Medford Oregon
Teva Investigational Site 10632 Portland Oregon
Teva Investigational Site 10639 Charleston South Carolina
Teva Investigational Site 10617 Spartanburg South Carolina
Teva Investigational Site 10630 Dallas Texas
Teva Investigational Site 10623 New Braunfels Texas
Teva Investigational Site 10638 San Antonio Texas

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01857323, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 7, 2015 · Synced Jul 23, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01857323 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →